AT437633T - Immunogenic compositions based on biodegradable microparticles containing a diphtheria and tetanus toxoid - Google Patents

Immunogenic compositions based on biodegradable microparticles containing a diphtheria and tetanus toxoid

Info

Publication number
AT437633T
AT437633T AT04776195T AT04776195T AT437633T AT 437633 T AT437633 T AT 437633T AT 04776195 T AT04776195 T AT 04776195T AT 04776195 T AT04776195 T AT 04776195T AT 437633 T AT437633 T AT 437633T
Authority
AT
Austria
Prior art keywords
diphtheria
immunogenic compositions
tetanus toxoid
compositions based
microparticles containing
Prior art date
Application number
AT04776195T
Other languages
German (de)
Inventor
Derek O'hagan
Manmohan Singh
Jina Kazzaz
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US47501003P priority Critical
Priority to US51307403P priority
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Priority to PCT/US2004/017125 priority patent/WO2005020964A1/en
Publication of AT437633T publication Critical patent/AT437633T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34278342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT437633(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio
    • Y02A50/466The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
AT04776195T 2003-06-02 2004-06-02 Immunogenic compositions based on biodegradable microparticles containing a diphtheria and tetanus toxoid AT437633T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US47501003P true 2003-06-02 2003-06-02
US51307403P true 2003-10-21 2003-10-21
PCT/US2004/017125 WO2005020964A1 (en) 2003-06-02 2004-06-02 Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen

Publications (1)

Publication Number Publication Date
AT437633T true AT437633T (en) 2009-08-15

Family

ID=34278342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776195T AT437633T (en) 2003-06-02 2004-06-02 Immunogenic compositions based on biodegradable microparticles containing a diphtheria and tetanus toxoid

Country Status (13)

Country Link
US (1) US9107831B2 (en)
EP (2) EP2179729B1 (en)
JP (3) JP5557415B2 (en)
CN (1) CN1798548B (en)
AT (1) AT437633T (en)
CA (1) CA2528007C (en)
CY (1) CY1109492T1 (en)
DE (1) DE602004022286D1 (en)
ES (2) ES2596553T3 (en)
HK (1) HK1087943A1 (en)
PL (1) PL1631264T5 (en)
PT (1) PT1631264E (en)
WO (1) WO2005020964A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
CA2511512C (en) * 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
US20070148188A1 (en) * 2003-07-30 2007-06-28 Merck & Co., Inc. Anthrax vaccine
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
US9107813B2 (en) 2004-11-15 2015-08-18 Derek T. O'Hagan Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
UA95237C2 (en) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Immunogenic composition
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
AU2015301368B2 (en) * 2014-08-07 2018-04-05 The United States Of America As Represented By The Secretary Of The Navy Immunogenic composition against Campylobacter jejuni
US9999591B2 (en) 2005-09-21 2018-06-19 The United States Of America As Represented By The Secretary Of The Navy Immunogenic composition against Campylobacter jejuni
AU2015321698B2 (en) * 2014-09-24 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct
JP5599975B2 (en) 2006-02-22 2014-10-01 マンカインド コーポレイション Method for improving the formulation properties of the fine particles containing diketopiperazine and an active agent
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
EP2357184B1 (en) * 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CN104288756A (en) * 2006-04-14 2015-01-21 曼金德公司 Glucagon-like peptide 1 (GLP-1) pharmaceutical formulations
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp Polynucleotide vector that comprises recombinant cell comprising the vector polypeptide, antibody, composition comprising the polynucleotide, vector, cell or recombinant polypeptide antibody, use of the composition and method for preparing the same composition and prepare a composi
WO2009017666A1 (en) * 2007-07-27 2009-02-05 The United States Of America As Represented By The Secretary Of The Navy Capsule composition for use as immunogen against campylobacter jejuni
EP2244695A1 (en) * 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
EP2254594B1 (en) 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
DK2570147T3 (en) 2008-06-13 2018-01-29 Mannkind Corp Dry powder inhaler and system for drug administration
RU2470681C2 (en) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Interactive system and method for real-time force profiling in inhalation
TWI614024B (en) 2008-08-11 2018-02-11 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp An apparatus, system and method for measuring resistance in an inhaler
BRPI1013154A2 (en) 2009-06-12 2016-04-05 Mannkind Corp microparticles of diketopiperazine with specific surface areas defined.
CN106421743A (en) * 2009-07-29 2017-02-22 贝恩德·赫尔穆特·阿达姆·雷姆 Polymer particles and uses thereof
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
WO2011150249A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
TW201221138A (en) 2010-08-23 2012-06-01 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
RU2546873C2 (en) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Non-lipidised variants of neisseria meningitidis orf2086 antigens
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
US20130142878A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
JP5925342B2 (en) 2012-03-09 2016-05-25 ファイザー・インク Neisseria meningitidis (Neisseriameningitidis) COMPOSITION AND PROCESS
MX2014014067A (en) * 2012-05-22 2015-02-04 Novartis Ag Meningococcus serogroup x conjugate.
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
ES2685894T3 (en) 2013-03-08 2018-10-15 Pfizer Inc. Immunogenic fusion polypeptides
CA2918369A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
KR20180099912A (en) 2013-09-08 2018-09-05 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
US20170000875A1 (en) * 2013-12-02 2017-01-05 Arytha Biosciences, Llc Toxoid preparation and uses thereof
CN106163504A (en) 2014-03-20 2016-11-23 加利福尼亚大学董事会 Hydrogel toxin-absorbing or binding nanoparticles
CN104225588B (en) * 2014-08-20 2016-06-22 北京智飞绿竹生物制药有限公司 Haemophilus influenzae type b vaccine preparation
CA2966754A1 (en) * 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1565298A (en) 1925-12-15 Stop check announcing device for adding machines
US715902A (en) 1902-03-10 1902-12-16 John Thomson Press Company Changer.
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
NL280826A (en) 1962-07-11
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1338800C (en) 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US4944331A (en) 1989-06-22 1990-07-31 Allied-Signal Inc. Solenoid valve
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Fiber hemagglutinin of Bordetella pertussis as carrier for conjugated vaccine.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Immunogenic detoxified mutants of cholera toxin and the toxin lt, their preparation and use for the preparation of vaccines
DE69334197T2 (en) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori cytotoxin used in vaccines and diagnostics
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
CZ282235B6 (en) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Inoculation substance, process of its preparation and use
FR2695563B1 (en) 1992-09-11 1994-12-02 Pasteur Institut Microparticles carrying antigens and their use in inducing humoral and cellular responses.
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
DK0678034T3 (en) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induction of cytotoxic T lymphocyte responses
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
DE69428136D1 (en) 1993-03-23 2001-10-04 Smithkline Beecham Biolog 3-0 Deazylierte monophosphoryl lipid A containing vaccine compositions
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
ES2267100T5 (en) 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
DE69738521T2 (en) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alpha virus vector having a reduced inhibition of the synthesis of cell macromolecules
US5759003A (en) 1996-07-22 1998-06-02 Greenway; John Michael Combined screw and clearance drill
DE19630390A1 (en) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteins, especially membrane proteins of Helicobacter pylori, their preparation and use
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugates immunostimulatory polynucleotide / immunomodulatory molecule.
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US20040022814A1 (en) 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
WO1998033487A1 (en) 1997-01-30 1998-08-06 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2301575C (en) 1997-05-20 2003-12-23 Heather L. Davis Vectors and methods for immunization or therapeutic protocols
ES2326848T3 (en) 1997-06-06 2009-10-20 Dynavax Technologies Corporation Inhibitors activity immunostimulatory DNA sequences.
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
ES2278420T3 (en) 1997-11-21 2007-08-01 Serono Genetics Institute S.A. genomic sequence and polypeptides of Chlamydia pneumoniae, fragments thereof and use thereof, particularly for diagnosis, prevention and treatment of infection.
EP2228384A1 (en) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
DK1042001T3 (en) 1997-12-16 2002-07-08 Chiron Corp Use of microparticles in combination with submicron (oil-in-water) emulsions
BR9906927A (en) 1998-01-14 2001-11-20 Chiron Spa Neisseria meningitidis protein
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6207171B1 (en) * 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
AT376591T (en) 1998-05-01 2007-11-15 Novartis Vaccines & Diagnostic Neisseria meningitidis antigenic and assortments
JP4601168B2 (en) 1998-07-29 2010-12-22 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Microparticles with adsorbed surface, a method of making it, and uses thereof
CN1338005A (en) 1998-10-09 2002-02-27 希龙公司 Neisseria genomic sequences and methods of their use
PT1126876E (en) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Adjuvant systems and vaccines
JP2002529069A (en) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2361582C (en) 1999-02-01 2010-04-06 Eisai Co., Ltd. Immunological adjuvant compound
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
PT1162999E (en) 1999-03-19 2007-02-28 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
EP1163002B1 (en) 1999-03-24 2008-08-06 The Secretary of State for Defence Polycationic carbohydrates as immunostimulants in vaccines
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CN1227030C (en) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CO5200837A1 (en) 1999-09-24 2002-09-27 Smithkline Beecham Corp vaccines
CZ20021045A3 (en) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Auxiliary preparation
AT332361T (en) 1999-11-19 2006-07-15 Chiron Corp Transfection and activation of dendritic cells by microparticle
AT413190T (en) 1999-12-01 2008-11-15 Novartis Vaccines & Diagnostic Eliciting antibodies specific for hepatitis C virus (HCV)
JP2003520248A (en) 2000-01-17 2003-07-02 カイロン エセ.ピー.アー. N. Outer membrane vesicles containing meningitidis serotype b outer membrane protein (OMV) vaccines
AU4938001A (en) 2000-03-22 2001-11-07 Chiron Corp Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
CN101428006A (en) * 2000-09-28 2009-05-13 诺华疫苗和诊断公司 Microparticle compositions and methods for the manufacture thereof
DE60118228T2 (en) 2000-09-28 2006-12-14 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Microparticles for administration of heterologous nucleic acid
NZ583028A (en) 2000-10-27 2011-10-28 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
EP1363663B1 (en) 2001-01-12 2011-03-02 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
GEP20053691B (en) * 2001-01-23 2005-12-12 Pasteur Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
CA2462646C (en) 2001-10-03 2013-02-12 Chiron Corporation Adjuvanted meningococcus compositions
PL367526A1 (en) 2001-06-29 2005-02-21 Chiron Corporation Hcv e1e2 vaccine compositions
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp Adjuvant compositions.
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
SE0201599D0 (en) * 2002-03-21 2002-05-30 Skyepharma Ab microparticles
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1904918A1 (en) 2005-06-29 2008-04-02 Nokia Corporation Smarter printing

Also Published As

Publication number Publication date
ES2328697T5 (en) 2017-07-25
EP2179729A1 (en) 2010-04-28
CN1798548A (en) 2006-07-05
CN1798548B (en) 2010-05-05
EP1631264A1 (en) 2006-03-08
EP1631264B1 (en) 2009-07-29
PL1631264T5 (en) 2018-09-28
JP2014111671A (en) 2014-06-19
CA2528007A1 (en) 2005-03-10
ES2596553T3 (en) 2017-01-10
JP2012082228A (en) 2012-04-26
WO2005020964A1 (en) 2005-03-10
US9107831B2 (en) 2015-08-18
US20050118275A1 (en) 2005-06-02
EP1631264B2 (en) 2017-03-08
HK1087943A1 (en) 2009-12-24
CY1109492T1 (en) 2014-08-13
DE602004022286D1 (en) 2009-09-10
CA2528007C (en) 2012-03-27
PT1631264E (en) 2009-11-03
JP2006526649A (en) 2006-11-24
ES2328697T3 (en) 2009-11-17
JP5557415B2 (en) 2014-07-23
EP1631264B8 (en) 2017-05-24
EP2179729B1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
DK1311759T3 (en) Dirvanordning for wind turbines
DK1448256T3 (en) safety needle
DE60142373D1 (en) The surgical stapler
DK1553608T3 (en) footswitch
DE60222415D1 (en) Absorbable polymer compositions
DE60313679D1 (en) Biodegradable and compostable containers
DE60108223D1 (en) Production and inventory on request
AT386909T (en) Wind turbine
DK1208214T3 (en) Genetically-engineered bleb vaccine
DE502004007158D1 (en) Arnordnung from a cervical prosthesis and insertion
DE60109447D1 (en) wind turbine
DE50104617D1 (en) Wind turbine
DK1372519T3 (en) implant
NO20054608D0 (en) Influenza vaccine
DK1199054T3 (en) liquefracture handpiece
DK1494993T3 (en) Novel curcumin analogues and uses thereof
NO20160430A1 (en) Grave Tooth tip and -adapteranordning
DK1269025T3 (en) thermokinetic compressor
DK1572728T3 (en) Polymer conjugates of reduced antigenicity, methods of making and uses thereof
NO20020449D0 (en) New natural resin formulations
NO20021399L (en) Kazolinderivater and their use as Pharmacists
AT421793T (en) Wind turbine
NO20013700L (en) GCSF conjugates
DK1537878T3 (en) Immunopotentiating compositions
DE60212473T8 (en) Code reader and entertainment system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1631264

Country of ref document: EP